High triglyceride levels alter the correlation of apolipoprotein B with low- and non-high-density lipoprotein cholesterol mostly in individuals with diabetes or metabolic syndrome

被引:20
|
作者
Barkas, Fotios [1 ]
Elisaf, Moses [1 ]
Liberopoulos, Evangelos [1 ]
Liontos, Angelos [1 ]
Rizos, Evangelos C. [1 ]
机构
[1] Univ Hosp Ioannina, Dept Internal Med, Ioannina, Greece
关键词
Apolipoprotein B; Low-density lipoprotein cholesterol; Non-high-density lipoprotein cholesterol; Diabetes; Metabolic syndrome; Triglycerides; NON-HDL-CHOLESTEROL; HIGH CARDIOVASCULAR RISK; APO-B; DYSLIPIDEMIA; GUIDELINES; STRATIFICATION; THERAPY; ESC/EAS; STATINS; INDEXES;
D O I
10.1016/j.atherosclerosis.2016.02.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To assess the correlation of Apolipoprotein B (Apo-B) with low-density (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) in untreated individuals attending a lipid clinic. Methods: This was a retrospective study conducted in Greece and including 1000 dyslipidemic subjects. We included individuals not taking lipid-lowering therapy at baseline visit and divided them in 2 groups: subjects diagnosed with diabetes or fulfilling the criteria of metabolic syndrome (MetS) and hyperlipidemic subjects without diabetes or MetS. The correlations (r(2)) of Apo-B with LDL-C and non-HDL-C were assessed in these 2 groups. Further analyses were performed according to the baseline triglyceride (TG) levels (<and >= 200 mg/dL). Results: From 821 eligible subjects, 51% were diagnosed with diabetes or MetS. The correlations between Apo-B and LDL-C or non-HDL-C were similar for the individuals with TG < 200 mg/dL. Specifically, Apo-B was significantly correlated with LDL-C (r(2) = 0.755, p < 0.01, for those with diabetes or MetS; r(2) = 0.848, p < 0.01, for non-diabetic and no MetS hyperlipidemic subjects). The corresponding correlations between Apo-B and non-HDL-C for the 2 groups were 0.743 and 0.838, respectively (p < 0.01). Although these correlations remained significant for the individuals with high TG levels (>= 200 mg/dL), the correlation factor was markedly decreased mostly in those with diabetes or MetS (r(2) = 0.600, p < 0.01, for the correlation between Apo-B and LDL-C; r(2) = 0.604, p < 0.01, for the correlation between Apo-B and nonHDL-C); in contrast, the corresponding correlations were stronger in the non-diabetic and no MetS hyperlipidemic individuals (r(2) = 0.710 and 0.714, respectively, p < 0.01). Conclusion: Apo-B correlation with both LDL-C and non-HDL-C is reduced in individuals with high TG levels and in particular for those with diabetes or MetS. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:58 / 63
页数:6
相关论文
共 50 条
  • [21] Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study)
    Robinson, Jennifer G.
    Ballantyne, Christie M.
    Hsueh, Willa
    Rosen, Jeffrey
    Lin, Jianxin
    Shah, Arvind
    Lowe, Robert S.
    Hanson, Mary E.
    Tershakovec, Andrew M.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2011, 5 (06) : 474 - 482
  • [22] Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein, Apolipoprotein, or Low-Density Lipoprotein Particle What Should Clinicians Measure?
    Davidson, Michael H.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (25) : 2616 - 2617
  • [23] Risk Factor Interactions, Non-High-Density Lipoprotein Cholesterol to Apolipoprotein B Ratio, and Severity of Coronary Arteriosclerosis in South Asian Individuals: An Observational Cohort Study
    Molina, Cesar R.
    Mathur, Ashish
    Soykan, Candan
    Sathe, Anita
    Kunhiraman, Leela
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (10):
  • [24] Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab
    Vallejo-Vaz, Antonio J.
    Leiter, Lawrence A.
    Del Prato, Stefano
    Taskinen, Marja-Riitta
    Mueller-Wieland, Dirk
    Bujas-Bobanovic, Maja
    Letierce, Alexia
    Mandel, Jonas
    Samuel, Rita
    Ray, Kausik K.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (15) : 1663 - 1674
  • [25] Usefulness of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as Predictors of Cardiovascular Disease in Chinese
    Gu, Xiaoying
    Yang, Xueli
    Li, Ying
    Cao, Jie
    Li, Jianxin
    Liu, Xiaoqing
    Chen, Jichun
    Shen, Chong
    Yu, Ling
    Huang, Jianfeng
    Gu, Dongfeng
    AMERICAN JOURNAL OF CARDIOLOGY, 2015, 116 (07) : 1063 - 1070
  • [26] Apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol Predictive value for CHD severity and prognostic utility in CHD patients
    Liting, P.
    Guoping, L.
    Zhenyue, C.
    HERZ, 2015, 40 : 1 - 7
  • [27] An alternative marker of low-density lipoprotein cholesterol in coronary artery disease: non-high-density lipoprotein cholesterol
    Ercan, Mujgan
    Oguz, Esra
    Yilmaz, Fatma Meric
    Bogdaycioglu, Nihal
    Unal, Kubranur
    Sahin, Deniz
    Uysal, Sema
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2015, 45 (01) : 153 - 158
  • [28] Utility of Non-High-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Evaluating Incident Diabetes Risk
    Sheng, Guotai
    Liu, Dingyang
    Kuang, Maobin
    Zhong, Yanjia
    Zhang, Shuhua
    Zou, Yang
    DIABETES METABOLIC SYNDROME AND OBESITY, 2022, 15 : 1677 - 1686
  • [29] Is Non-High-Density Lipoprotein Cholesterol a Marker and Therapeutic Target for Dyslipidemia in Metabolic Syndrome?
    Vega, Gloria Lena
    METABOLIC SYNDROME AND RELATED DISORDERS, 2014, 12 (09) : 451 - 453
  • [30] Apolipoprotein B versus non-high-density lipoprotein cholesterol: contradictory results in the same journal
    Sniderman, Allan D.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2022, 29 (18) : 2347 - 2348